Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhulun Wang

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Science Translational Medicine|December 1, 2012
Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complexIan N Foltz, Sylvia Hu, Chadwick King, et al.
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure guided design of a series of sphingosine kinase (SphK) inhibitorsDarin J Gustin, Yihong Li, Matthew L Brown, et al.
Science Translational Medicine|December 21, 2018
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical modelsElizabeth A Killion, Jinghong Wang, Junming Yie, et al.
Antibody Therapeutics|July 1, 2026
TROP2 antibody-drug conjugate: unique epitope engagement drives differentiated efficacyHang Chen, Xiaoshan Min, Qingwen Cheng, et al.
Bioorganic & Medicinal Chemistry|January 9, 2013
Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivityJoshua P Taygerly, Lawrence R McGee, Steven M Rubenstein, et al.
Journal of Medicinal Chemistry|March 20, 2014
Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3Zhihong Li, Xianghong Wang, John Eksterowicz, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Science Translational Medicine|December 1, 2012
Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complexIan N Foltz, Sylvia Hu, Chadwick King, et al.
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure guided design of a series of sphingosine kinase (SphK) inhibitorsDarin J Gustin, Yihong Li, Matthew L Brown, et al.
Science Translational Medicine|December 21, 2018
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical modelsElizabeth A Killion, Jinghong Wang, Junming Yie, et al.
Antibody Therapeutics|July 1, 2026
TROP2 antibody-drug conjugate: unique epitope engagement drives differentiated efficacyHang Chen, Xiaoshan Min, Qingwen Cheng, et al.
Bioorganic & Medicinal Chemistry|January 9, 2013
Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivityJoshua P Taygerly, Lawrence R McGee, Steven M Rubenstein, et al.
Journal of Medicinal Chemistry|March 20, 2014
Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3Zhihong Li, Xianghong Wang, John Eksterowicz, et al.
Pageof 7